TABLE 1.

Patient Characteristics

Patient no.	Age (y)	Sex	Histology	Tumor sites (primary and metastatic)	Eastern Cooperative Oncology group	No. of previous systemic therapies	Concomitant therapy	Subsequent therapy	⁶⁸Ga-FAPI-46 (SUV_max baseline)	Status	Follow-up (d)
1	22	Male	Osteosarcoma	Lung, heart, lymph nodes	2	7	—	—	12.1	Dead	24
2	66	Male	Chordoma	Bone, soft tissue, liver, lung, lymph nodes	3	2	—	Nivolumab	22.3	Dead	67
3	54	Female	Fibrosarcoma	Lung, lymph nodes, pancreas, bone	1	6	—	—	18.3	Follow-up	100
4	57	Female	PDAC	Liver, lung, lymph nodes, bone	3	2	—	Cisplatin	14.9	Dead	57
5	61	Female	PDAC	Pancreas, liver, lung, lymph nodes, bone	2	9	Trametinib	—	19.4	Dead	41
6	56	Female	PDAC	Pancreas, liver, lung, lymph nodes, kidney	2	6		—	16.5	Dead	105
7	63	Female	GNET	Lung, liver, lymph nodes, bone, soft tissue	1	3	—	Nivolumab	16.1	Follow-up	44
8	61	Male	Conventional chondrosarcoma	Lung, lymph nodes, pancreas, bone	2	1	—	—	16.7	Follow-up	36
9	56	Male	Spindle cell sarcoma	Kidney, liver, lung pleura	1	6	—	—	28	Follow-up	36

PDAC = pancreatic ductal adenocarcinoma; GNET = gastrointestinal neuroectodermal tumor.